These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 29729689)

  • 21. Genomic and Epigenomic Profile of Uterine Smooth Muscle Tumors of Uncertain Malignant Potential (STUMPs) Revealed Similarities and Differences with Leiomyomas and Leiomyosarcomas.
    Conconi D; Redaelli S; Lissoni AA; Cilibrasi C; Perego P; Gautiero E; Sala E; Paderno M; Dalprà L; Landoni F; Lavitrano M; Roversi G; Bentivegna A
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
    Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
    Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Raf kinase inhibitor protein expression in smooth muscle tumours of the uterus: a diagnostic marker for leiomyosarcoma?
    Greco S; Pinheiro J; Cardoso-Carneiro D; Giantomassi F; Pellegrino P; Scaglione G; Delli Carpini G; Ciavattini A; Zannoni GF; Goteri G; Martinho O; Ciarmela P
    Reprod Biomed Online; 2024 Jun; 48(6):103816. PubMed ID: 38608337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fascin expression in uterine smooth muscle tumors.
    Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B
    Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular prognostication of uterine smooth muscle neoplasms: From CGH array to CINSARC signature and beyond.
    Croce S; Chibon F
    Genes Chromosomes Cancer; 2021 Mar; 60(3):129-137. PubMed ID: 33099852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors.
    Croce S; Ducoulombier A; Ribeiro A; Lesluyes T; Noel JC; Amant F; Guillou L; Stoeckle E; Devouassoux-Shisheboran M; Penel N; Floquet A; Arnould L; Guyon F; Mishellany F; Chakiba C; Cuppens T; Zikan M; Leroux A; Frouin E; Farre I; Genestie C; Valo I; MacGrogan G; Chibon F
    Mod Pathol; 2018 May; 31(5):816-828. PubMed ID: 29327710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The selected biomarker analysis in 5 types of uterine smooth muscle tumors.
    Zhang Q; Kanis MJ; Ubago J; Liu D; Scholtens DM; Strohl AE; Lurain JR; Shahabi S; Kong B; Wei JJ
    Hum Pathol; 2018 Jun; 76():17-27. PubMed ID: 29258902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns of bone morphogenetic protein-2 expression in smooth muscle tumors of the uterine corpus and other uterine tissues.
    Fadare O; Renshaw IL; Liang SX
    Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):352-9. PubMed ID: 21285872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors.
    Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
    Fertil Steril; 2004 Apr; 81(4):1062-6. PubMed ID: 15066464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of cyclooxygenase-2, c-kit, progesterone and estrogen receptors in uterine smooth muscle tumors: differential diagnosis.
    Comunoğlu NU; Durak H; Comunoğlu C; Ekici AI; Ozkan F; Akyildiz EU; Ilvan S; Calay Z; Molinas N
    APMIS; 2007 Jun; 115(6):726-35. PubMed ID: 17550381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. POTENTIAL LIFE PROGNOSTIC MARKER FOR MESENCHYMAL TUMOR RESEMBLING UTERINE LEIOMYOSARCOMA.
    Nishikawa S; Hayashi T; Uzaki T; Yaegashi N; Abiko K; Konishi I
    Georgian Med News; 2023 Oct; (343):119-126. PubMed ID: 38096528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of allelic loss as an adjuvant tool in evaluation of malignancy in uterine smooth muscle tumors.
    Esposito NN; Hunt JL; Bakker A; Jones MW
    Am J Surg Pathol; 2006 Jan; 30(1):97-103. PubMed ID: 16330948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-L1 Expression and Tumor-infiltrating Lymphocytes in Uterine Smooth Muscle Tumors: Implications for Immunotherapy.
    Shanes ED; Friedman LA; Mills AM
    Am J Surg Pathol; 2019 Jun; 43(6):792-801. PubMed ID: 31009388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD147 expression in uterine smooth muscle tumors, and its potential role as a diagnostic and prognostic marker in patients with leiomyosarcoma.
    Ozler A; Evsen MS; Turgut A; Sak ME; Tunc SY; Agacayak E; Alabalik U; Basaranoglu S; Keles AN; Gul T
    J Exp Ther Oncol; 2014; 10(4):325-30. PubMed ID: 25509988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.
    Allen MM; Douds JJ; Liang SX; Desouki MM; Parkash V; Fadare O
    Int J Clin Exp Pathol; 2015; 8(3):2795-801. PubMed ID: 26045786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic value of progesterone receptor, p16, p53 and pHH3 expression in uterine atypical leiomyoma.
    Liang Y; Zhang X; Chen X; Lü W
    Int J Clin Exp Pathol; 2015; 8(6):7196-202. PubMed ID: 26261614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD56 is Expressed in Uterine Smooth Muscle Tumors.
    Karpathiou G; Chauleur C; Papoudou-Bai A; Dagher S; Peoc'h M
    Int J Gynecol Pathol; 2021 Jul; 40(4):315-323. PubMed ID: 32897962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inguinal smooth muscle tumors in women-a dichotomous group consisting of Müllerian-type leiomyomas and soft tissue leiomyosarcomas: an analysis of 55 cases.
    Patil DT; Laskin WB; Fetsch JF; Miettinen M
    Am J Surg Pathol; 2011 Mar; 35(3):315-24. PubMed ID: 21297441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Practical diagnostic aspects of uterine leiomyosarcoma in the context of the 2020 WHO classification].
    Horn LC; Hiller GGR; Mayr D; Schmoeckel E; Höhn AK
    Pathologe; 2022 May; 43(3):196-201. PubMed ID: 35412039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. h-Caldesmon in leiomyosarcoma and tumors with smooth muscle cell-like differentiation: its specific expression in the smooth muscle cell tumor.
    Watanabe K; Kusakabe T; Hoshi N; Saito A; Suzuki T
    Hum Pathol; 1999 Apr; 30(4):392-6. PubMed ID: 10208459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.